Felip Burgos

Standardisation of spirometry

[⇓][1] SERIES “ATS/ERS TASK FORCE: STANDARDISATION OF LUNG FUNCTION TESTING” Edited by V. Brusasco, R. Crapo and G. Viegi Number 2 in this Series [1]: #F13

Interpretative strategies for lung function tests

SERIES “ATS/ERS TASK FORCE: STANDARDISATION OF LUNG FUNCTION TESTING” Edited by V. Brusasco, R. Crapo and G. Viegi Number 5 in this Series This section is written to provide guidance in interpreting pulmonary function tests (PFTs) to medical directors of hospital-based laboratories that perform PFTs, and physicians who are responsible for interpreting the results of PFTs most commonly ordered for clinical purposes. Specifically, this section addresses the interpretation of spirometry, bronchodilator response, carbon monoxide diffusing capacity ( D L,CO) and lung volumes. The sources of variation in lung function testing and technical aspects of spirometry, lung volume measurements and D L,CO measurement have been considered in other documents published in this series of Task Force reports 1–4 and in the American Thoracic Society (ATS) interpretative strategies document 5. An interpretation begins with a review and comment on test quality. Tests that are less than optimal may still contain useful information, but interpreters should identify the problems and the direction and magnitude of the potential errors. Omitting the quality review and relying only on numerical results for clinical decision making is a common mistake, which is more easily made by those who are dependent upon computer interpretations. Once quality has been assured, the next steps involve a series of comparisons 6 that include comparisons of test results with reference values based on healthy subjects 5, comparisons with known disease or abnormal physiological patterns ( i.e. obstruction and restriction), and comparisons with self, a rather formal term for evaluating change in an individual patient. A final step in the lung function report is to answer the clinical question that prompted the test. Poor choices made during these preparatory steps increase the risk of misclassification, i.e. a falsely negative or falsely positive interpretation for a lung function abnormality or a change …

Standardisation of the measurement of lung volumes

[⇓][1] SERIES “ATS/ERS TASK FORCE: STANDARDISATION OF LUNG FUNCTION TESTING” Edited by V. Brusasco, R. Crapo and G. Viegi Number 3 in this Series [1]: #F7

Standardisation of the single-breath determination of carbon monoxide uptake in the lung

[⇓][1] SERIES “ATS/ERS TASK FORCE: STANDARDISATION OF LUNG FUNCTION TESTING” Edited by V. Brusasco, R. Crapo and G. Viegi Number 4 in this Series [1]: #F4

General considerations for lung function testing.

SERIES “ATS/ERS TASK FORCE: STANDARDISATION OF LUNG FUNCTION TESTING” Edited by V. Brusasco, R. Crapo and G. Viegi Number 1 in this Series ⇓In preparing the joint statements on lung function testing for the American Thoracic Society (ATS) and the European Respiratory Society (ERS), it was agreed by the working party that the format of the statements should be modified so that they were easier to use by both technical and clinical staff. This statement contains details about procedures that are common for many methods of lung function testing and, hence, are presented on their own. A list of abbreviations used in all the documents is also included as part of this statement. All terms and abbreviations used here are based on a report of the American College of Chest Physicians/ATS Joint Committee on Pulmonary Nomenclature 1. The metrology definitions agreed by the International Standards Organization (ISO) are recommended 2 and some important terms are defined as follows. Accuracy is the closeness of agreement between the result of a measurement and the conventional true value. Repeatability is the closeness of agreement between the results of successive measurements of the same item carried out, subject to all of the following conditions: same method, same observer, same instrument, same location, same condition of use, and repeated over a short space of time. In previous documents, the term reproducibility was used in this context, and this represents a change towards bringing this document in line with the ISO. Reproducibility is the closeness of agreement of the results of successive measurements of the same item where the individual measurements are carried out with changed conditions, such as: method of measurement, observer, instrument, location, conditions of use, and time. Thus, if a technician tests a subject several times, this is looking at the …

PREDICTION EQUATIONS FOR PLETHYSMOGRAPHIC LUNG VOLUMES

Due to the lack of information of reference values for plethysmographic lung volumes, standardized measurements were carried out on a selected sample of 482 healthy non-smoking volunteers (300 men and 182 women), aged 20-70 years, living in the Barcelona area (Spain). Prediction equations using age, height and body surface area (BSA) as covariates were calculated for the subdivisions of lung volumes [TLC, IC, EVC, FRC, RV and RV/TLC (%)], separately for both sexes. Simple linear equations predicted lung volumes as well as more complex equational models. BSA correction was useful for FRC but not for the other parameters. Our predicted FRC was up to 10% higher (mean 256 ml) than the FRC estimated by other studies using gas dilution techniques, but showed an acceptable agreement with the plethysmographic measurements carried out in an independent sample of 94 healthy non-smokers (42 men and 52 women) from Barcelona using different equipment. The present study provides an internally consistent set of prediction equations for static lung volumes. Differences in predicted FRC between the present study and other reference values obtained using gas dilution measurements should be attributed to the method of measurement.

Effects of nebulized NG-nitro-L-arginine methyl ester in patients with hepatopulmonary syndrome†‡

Enhanced pulmonary production of nitric oxide (NO) has been implicated in the pathogenesis of hepatopulmonary syndrome (HPS). NO inhibition with NG‐nitro‐L‐arginine methyl ester (L‐NAME) in both animals and humans with HPS has improved arterial hypoxemia. We assessed the role of enhanced NO production in the pathobiology of arterial deoxygenation in HPS and the potential therapeutic efficacy of selective pulmonary NO inhibition. We investigated the effects of nebulized L‐NAME (162.0 mg) at 30 and 120 minutes on all intrapulmonary and extrapulmonary factors governing pulmonary gas exchange in 10 patients with HPS (60 ± 7 [SD] yr; alveolar–arterial oxygen gradient, range 19–76 mm Hg; arterial oxygen tension, range 37–89 mm Hg). Nebulized L‐NAME maximally decreased exhaled NO (by −55%; P < .001), mixed venous nitrite/nitrate (by −12%; P = .02), and cardiac output (by −11%; P = .002) while increased systemic vascular resistance (by 11%; P = .008) and pulmonary vascular resistance (by 25%; P = .03). In contrast, ventilation‐perfusion mismatching, intrapulmonary shunt and, in turn, arterial deoxygenation remained unchanged. In conclusion, gas exchange disturbances in HPS may be related to pulmonary vascular remodeling rather than to an ongoing vasodilator effect of enhanced NO production. (HEPATOLOGY 2006;43:1084–1091.)

Definition of COPD: based on evidence or opinion?

To the Editors: In 1986, the American Thoracic Society (ATS) first suggested a fixed ratio of forced expiratory volume in one second (FEV1) to forced vital capacity (FVC) <0.75 to define airflow obstruction 1. Subsequent ATS documents published in 1991 2 and 1995 3 generically defined airflow obstruction as a reduction of FEV1/FVC, without recommending any numerical cut-off point. By contrast, the European Respiratory Society (ERS) guidelines 4 suggested the diagnosis of airflow obstruction be based on a ratio of FEV1 to slow vital capacity (VC) <88 and <89% of predicted in males and females, respectively. These values were not arbitrarily chosen as they roughly correspond to the lower 95th percentiles of frequency distributions of a healthy population. More importantly, they are consistent with the well-known decrease of lung elastic recoil and, by inference, of forced expiratory flow with ageing. In 2001, the Global Initiative for …

2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung

This document provides an update to the European Respiratory Society (ERS)/American Thoracic Society (ATS) technical standards for single-breath carbon monoxide uptake in the lung that was last updated in 2005. Although both DLCO (diffusing capacity) and TLCO (transfer factor) are valid terms to describe the uptake of carbon monoxide in the lung, the term DLCO is used in this document. A joint taskforce appointed by the ERS and ATS reviewed the recent literature on the measurement of DLCO and surveyed the current technical capabilities of instrumentation being manufactured around the world. The recommendations in this document represent the consensus of the taskforce members in regard to the evidence available for various aspects of DLCO measurement. Furthermore, it reflects the expert opinion of the taskforce members on areas in which peer-reviewed evidence was either not available or was incomplete. The major changes in these technical standards relate to DLCO measurement with systems using rapidly responding gas analysers for carbon monoxide and the tracer gas, which are now the most common type of DLCO instrumentation being manufactured. Technical improvements and the increased capability afforded by these new systems permit enhanced measurement of DLCO and the opportunity to include other optional measures of lung function. Updated technical standards for measuring DLCO (TLCO) including the use of rapid gas analyser systems http://ow.ly/QUhv304PMsy

Assessment of acute pulmonary vascular reactivity in portopulmonary hypertension

The role of acute pulmonary vasodilator testing in portopulmonary hypertension (PoPH), a current contraindication for orthotopic liver transplantation (OLT), has not been thoroughly elucidated. The purpose of this work was to analyze the results of acute vasodilator testing with inhaled nitric oxide (NO), to compare them with intravenous epoprostenol (PGI2), and to investigate the acute effects of the oral vasodilator isosorbide‐5‐mononitrate (Is‐5‐MN), in patients with PoPH. A total of 19 patients with PoPH (male/female = 9/10) were studied. Pulmonary hemodynamic measurements were performed at baseline and during NO inhalation (40 ppm); additionally, 15 patients were tested with PGI2 (2–12 μg/kg/minute) and 8 were tested with Is‐5‐MN (20–40 mg). Inhaled NO reduced pulmonary artery pressure (PAP) and pulmonary vascular resistance (PVR) by 5.7% and 11.0%, respectively. PGI2 elicited greater reductions in PAP (11.8%) and PVR (−24.0%), and produced a 28% drop in systemic vascular resistance (SVR) and a 17% increase in the cardiac index (CI). Is‐5‐MN reduced PAP by 25.6% and PVR by 21.5%, without systemic changes. There was good agreement between the response to PGI2 and Is‐5‐MN: 6 patients of the whole series (32%) decreased PAP >20% from baseline, reaching a final value ≤35 mmHg, the current limit for OLT. In conclusion, acute vasodilator testing has a relevant role in PoPH, as it identifies one‐third of patients able to reach a more favorable hemodynamic situation, which can be determinant for their management. For vasodilator testing, PGI2 is more suitable than NO in PoPH. Is‐5‐MN exerts a selective effect on pulmonary circulation in patients who had already responded to PGI2. Liver Transpl 13:1506–1514, 2007.